CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 104; no. 1; pp. 139 - 144
• Main Authors: McAllister-Lucas, Linda M, Ruland, Jürgen, Siu, Katy, Jin, Xiaohong, Gu, Shufang, Kim, David S L, Kuffa, Peter, Kohrt, Dawn, Mak, Tak W, Nuñez, Gabriel, Lucas, Peter C
• Format: Journal Article
• Language: English
• Published: United States 02-01-2007
• Subjects: Adaptor Proteins, Signal Transducing - physiology; Angiotensin II - pharmacology; Animals; Apoptosis Regulatory Proteins - physiology; B-Cell CLL-Lymphoma 10 Protein; CARD Signaling Adaptor Proteins - physiology; Caspases - physiology; Hepatocytes - metabolism; Humans; I-kappa B Kinase - metabolism; Inflammation - etiology; Mice; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein; Neoplasm Proteins - physiology; NF-kappa B - metabolism; Receptor, Angiotensin, Type 1 - physiology; Signal Transduction - physiology; Ubiquitin - metabolism
• ISSN: 0027-8424

Angiotensin II (Ang II) is a peptide hormone that, like many cytokines, acts as a proinflammatory agent and growth factor. After injury to the liver, the hormone assists in tissue repair by stimulating hepatocytes and hepatic stellate cells to synthesize extracellular matrix proteins and secrete secondary cytokines and by stimulating myofibroblasts to proliferate. However, under conditions of chronic liver injury, all of these effects conspire to promote pathologic liver fibrosis. Much of this effect of Ang II results from activation of the proinflammatory NF-kappaB transcription factor in response to stimulation of the type 1 Ang II receptor, a G protein-coupled receptor. Here, we characterize a previously undescribed signaling pathway mediating Ang II-dependent activation of NF-kappaB, which is composed of three principal proteins, CARMA3, Bcl10, and MALT1. Blocking the function of any of these proteins, through the use of either dominant-negative mutants, RNAi, or gene targeting, effectively abolishes Ang II-dependent NF-kappaB activation in hepatocytes. In addition, Bcl10(-/-) mice show defective hepatic cytokine production after Ang II treatment. Evidence also is presented that this pathway activates NF-kappaB through ubiquitination of IKKgamma, the regulatory subunit of the IkappaB kinase complex. These results elucidate a concrete series of molecular events that link ligand activation of the type 1 Ang II receptor to stimulation of the NF-kappaB transcription factor. These findings also uncover a function of the CARMA, Bcl10, and MALT1 proteins in cells outside the immune system.